Literature DB >> 34730396

iTRAQ-Based Proteomics Analysis of Human Cytomegalovirus Latency and Reactivation in T98G Cells.

Shuang Cheng1, Fei Zhao2,3, Le Wen4,5, Bo Yang4,5, Xian-Zhang Wang1,6, Sheng-Nan Huang1,6, Xuan Jiang4,5, Wen-Bo Zeng1, Jin-Yan Sun1, Fu-Kun Zhang7, Hong-Jie Shen7, Elizabeth Fortunato8, Min-Hua Luo1,6,9, Han Cheng9.   

Abstract

Human cytomegalovirus (HCMV) establishes a persistent/latent infection after primary infection, and the host factor(s) plays a key role in regulating HCMV infection status. The spread of reactivated HCMV via the hematogenous or neural route usually results in severe diseases in newborns and immunocompromised individuals. As the primary reservoirs in vivo, cells of myeloid lineage have been utilized extensively to study HCMV infection. However, the molecular mechanism of HCMV latency/reactivation in neural cells is still poorly understood. We previously showed that HCMV-infected T98G cells maintain a large number of viral genomes and support HCMV reactivation from latency upon cAMP/IBMX treatment. Here, we employed an isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics to characterize cellular protein changes during HCMV latency and reactivation in T98G cells. A total of 168 differentially expressed proteins (DEPs) were identified, including 89 proteins in latency and 85 proteins in reactivation. Bioinformatics analysis showed that a few biological pathways were associated with HCMV latency or reactivation. Moreover, we validated 16 DEPs by both mRNA and protein expression profiles and further evaluated the effects of ApoE and the phosphatidylinositol 3-kinase (PI3K) pathway on HCMV infection. ApoE knockdown reduced HCMV loads and virus release, whereas overexpressing ApoE hampered HCMV latent infection, indicating a role in HCMV latency establishment/maintenance. Blocking the PI3K pathway by LY294002, a PI3K inhibitor, induced HCMV reactivation from latency in T98G cells. Overall, this comparative proteomics analysis delineates the cellular protein changes during HCMV latency and reactivation and provides a road map to advance our understanding of the mechanism(s) in the context of neural cells. IMPORTANCE Human cytomegalovirus (HCMV) is a highly transmissible betaherpesvirus that has a prevalence of 60% to 90% worldwide. This opportunist pathogen poses a significant threat to newborns and immunosuppressed individuals. One major obstacle for developing effective therapeutics is a poor understanding of HCMV latency/reactivation mechanisms. This study presents, for the first time, a systemic analysis of host cell protein expression changes during HCMV latency establishment and reactivation processes in neural cells. We showed that ApoE was downregulated by HCMV to facilitate latent infection. Also, the proteomics analysis has associated a few PI3K pathway-related proteins with HCMV reactivation. Altogether, this study highlights multiple host proteins and signaling pathways that can be further investigated as potential druggable targets for HCMV-related diseases, especially brain disorders.

Entities:  

Keywords:  ApoE; PI3K; T98G cells; human cytomegalovirus; iTRAQ proteomics; latency; reactivation

Mesh:

Substances:

Year:  2021        PMID: 34730396      PMCID: PMC8791298          DOI: 10.1128/JVI.01476-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  71 in total

1.  Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome.

Authors:  C A Bolovan-Fritts; E S Mocarski; J A Wiedeman
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

2.  Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes.

Authors:  A Marchini; H Liu; H Zhu
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Influence of histone H1 on chromatin structure.

Authors:  F Thoma; T Koller
Journal:  Cell       Date:  1977-09       Impact factor: 41.582

4.  Later passages of neural progenitor cells from neonatal brain are more permissive for human cytomegalovirus infection.

Authors:  Xing Pan; Xiao-Jun Li; Xi-Juan Liu; Hui Yuan; Jia-Fu Li; Ying-Liang Duan; Han-Qing Ye; Ya-Ru Fu; Guan-Hua Qiao; Cong-Cong Wu; Bo Yang; Xiao-Hui Tian; Kang-Hong Hu; Ling-Feng Miao; Xiao-Ling Chen; Jun Zheng; Simon Rayner; Philip H Schwartz; William J Britt; Jiang Xu; Min-Hua Luo
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

Review 5.  The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

Authors:  Mark R Wills; Emma Poole; Betty Lau; Ben Krishna; John H Sinclair
Journal:  Cell Mol Immunol       Date:  2014-08-18       Impact factor: 11.530

6.  A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny.

Authors:  Christine M O'Connor; Eain A Murphy
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

7.  Neonatal neural progenitor cells and their neuronal and glial cell derivatives are fully permissive for human cytomegalovirus infection.

Authors:  Min Hua Luo; Philip H Schwartz; Elizabeth A Fortunato
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 8.  Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease.

Authors:  W Britt
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

9.  Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection.

Authors:  Michael P Weekes; Shireen Y L Tan; Emma Poole; Suzanne Talbot; Robin Antrobus; Duncan L Smith; Christina Montag; Steven P Gygi; John H Sinclair; Paul J Lehner
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

10.  Opposing Regulation of the EGF Receptor: A Molecular Switch Controlling Cytomegalovirus Latency and Replication.

Authors:  Jason Buehler; Sebastian Zeltzer; Justin Reitsma; Alex Petrucelli; Mahadevaiah Umashankar; Mike Rak; Patricia Zagallo; Joyce Schroeder; Scott Terhune; Felicia Goodrum
Journal:  PLoS Pathog       Date:  2016-05-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.